


**PATIENT**

Gizmo Turner

**PRESENTING CLINICAL SIGNS**

 History: Recheck echo. Has developed exercise-induced cough.  
 -Current medications: Pimobendan 0.75mg CAP 1 tablet BID + Fortekor 2.5mg 1/2 tablet BID.  
 -Pertinent previous echo findings (3/2022 MML): Severe MR, moderate LAE, mild LVE, mild TR. LA; 1.9, LV: 2.5.

**SPECIES**

Canine

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and doppler imaging is available. Mildly thickening of mitral valve leaflets (anterior&gt;posterior) with mild prolapse into the left atrial lumen. Moderate to severe eccentric mitral regurgitation with moderate left atrial dilation. Normal MR velocity. Mildly increased LV diameter with hyperdynamic myocardial function. The tricuspid valve appears mildly thickened with mild tricuspid regurgitation. Normal velocity. Normal right atrial and ventricular diameter. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. No aortic or pulmonic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed.

**BREED**

Chihuahua

**SEX**

Male Neutered

**AGE**

14 years

**CARDIAC CHART**
**WEIGHT**

6.3lbs

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.4	2.7	1.8	1.8	53	86	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	167	1.2	0.64	2.86	1.0	2.3	1.1
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
<b>BODY WEIGHT DEPENDENT PARAMETERS</b>				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

**INTERPRETED BY**

 Maggie Machen Lamy,  
 DVM DACVIM  
 (Cardiology)

**IMAGING PERFORMED BY**

Kelly Reschny, RVT

**HOSPITAL NAME**

 Burlington Lakeshore  
 Veterinary Hospital

**REFERRING VET**

Dr. Aziz

**INVOICE**

25892

**DATE**

8/19/22

**INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

Chronic degenerative valve disease persists with evidence stability. Severe mitral and mild tricuspid regurgitation are unchanged with stable left and right heart dimensions. No development of pulmonary hypertension or other concurrent issues are noted in this study.

Given these findings and the nature of the symptom, the cough is likely multi-factorial in origin with some degree of concurrent airway disease suspected. Baseline CXR are



**PATIENT**

Gizmo Turner

strongly recommended. Hydrocodone should be considered to maintain quality of life. Continue two medications as previously prescribed with no additional medications warranted at this time. Assessment of progression in the future will help predict long term outcome, however prognosis is guarded at this stage (B2).

**SPECIES**

Canine

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.

**BREED**

Chihuahua

Anesthetic risk is considered moderately elevated. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated. Avoid alpha2 agonists such as Dexdomitor in this patient.

**SEX**

Male Neutered

**AGE**

14 years

**PLAN**

Baseline BP recommended every 6 months. Continue Benazepril and Pimobendan as prescribed. Consider Hydrocodone and CXR as discussed.

**WEIGHT**


6.3lbs

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.

**IMAGES**

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM DACVIM  
(Cardiology)



**IMAGING PERFORMED BY**

Kelly Reschny, RVT

**HOSPITAL NAME**

Burlington Lakeshore  
Veterinary Hospital

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

**REFERRING VET**

Dr. Aziz

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

**INVOICE**

25892

Maggie Machen Lamy, DVM  
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)  
info@sonopath.com

**DATE**

8/19/22